bwin±ØÓ®Ò½Ò©ÉÌÒµ»¯Æ½Ì¨ÓÖÌíÐÂÏàÖú£¬£¬ £¬£¬£¬ÔÙ¶ÈЯÊÖ°²Ë¹Ì©À´¹²ÍذÐÏòÒ©Èë¿ÚÐÂÆªÕÂ
2020-12-16

12ÔÂ16ÈÕ£¬£¬ £¬£¬£¬°²Ë¹Ì©À´ÖÆÒ©£¨Öйú£©ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°°²Ë¹Ì©À´¡±£©Óëbwin±ØÓ®£¨ÒÔϼò³Æ¡°bwin±ØÓ®Ò½Ò©¡±£©ÔÚ±±¾©¾ÙÐÐÁËXOSPATA?£¨Ó¢ÎÄͨÓÃÃû£ºgilteritinib fumarate tablets£¬£¬ £¬£¬£¬ÖÐÎÄͨÓÃÃû£º¸»ÂíËἪÈðÌæÄáÆ¬£¬£¬ £¬£¬£¬ÒÔÏÂͳ³ÆÎª¡°XOSPATA¡±£©Èë¿ÚºÍ×ܾ­ÏúÏà¹ØµÄÏàÖúÒâÏòÊéǩԼÒÇʽ¡£¡£¡£Õ⽫µÓڨ˫·½ÔÚÈë¿ÚÒ©ÁìÓòÊ׸ö²úÆ·µÄÏàÖú»ù´¡¡£¡£¡£


1646371909375908lw7M.jpeg

ǩԼÒÇʽºÏÓ°


´Ëǰ£¬£¬ £¬£¬£¬bwin±ØÓ®Ò½Ò©ÒÑÓ밲˹̩À´¾ÍÆìϵĹþÀֺͷƲ¼Á¦Æ·ÅƸ濢սÂÔÏàÖú£¬£¬ £¬£¬£¬ÔÚ¶à¸ö¼²²¡ÁìÓòΪÖйú»¼ÕßÌṩ¿µ½¡Ð§ÀÍ¡£¡£¡£´Ë´ÎË«·½ÔÙ¶ÈЯÊÖ£¬£¬ £¬£¬£¬Ð­Á¦ÍƽøXOSPATA½øÈëÖйúÊг¡£¡£¡£¬£¬ £¬£¬£¬½«Ìî²¹º£ÄÚÓÉFLT3»ùÒòÍ»±äÄÑÖÎÐÔ»ò¸´·¢ÐÔ¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¨AML£©»¼ÕßÎÞ»ñÅú°ÐÏòÒ©¿ÉÓõĿÕȱ£¬£¬ £¬£¬£¬ÎªAML³ÉÈË»¼Õß´øÀ´ÐµÄÖÎÁƼƻ®¡£¡£¡£


º£ÄÚÊ׸ö¶þ´úFLT3°ÐÏòÒ©£¬£¬ £¬£¬£¬½«´øÀ´Í»ÆÆÐÔÖÎÁƼƻ®

¾ÝÏà¹ØÍ³¼Æ£¬£¬ £¬£¬£¬ÎÒ¹úÿÄêÔ¼ÓÐ8ÍòÈËÕï¶Ï»¼Óа×Ѫ²¡1£¬£¬ £¬£¬£¬¶ø¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¨AML£©ÊdzÉÄêÈ˳£¼ûµÄ°×Ѫ²¡ÀàÐÍÖ®Ò»2£¬£¬ £¬£¬£¬ÊÇÒ»ÖÖ¶ÔѪҺºÍ¹ÇËèÇÖÏ®ÐÔÇ¿¡¢Ï£ÍûѸËٵĶñÐÔÖ×Áö£¬£¬ £¬£¬£¬¸Ã¼²²¡ÒÔÔ¤ºó½Ï²î¡¢ÉúÑÄÆÚ¶Ì¡¢ÉúÑÄÂʼ«µÍÖø³Æ£¬£¬ £¬£¬£¬ÊÇÈÝÒ׸´·¢µÄÄÑÖβ¡£¡£¡£¬£¬ £¬£¬£¬Æä·¢²¡ÂÊËæ×ÅÄêËêµÄÔöÌí¶øÉý¸ß3¡£¡£¡£ÔÚAMLµÄ»¼²¡ÈºÌåÖУ¬£¬ £¬£¬£¬ÓÐÔ¼25%¡ª30%µÄ»¼ÕßÓÐFMSÑùÀÒ°±Ëἤø3£¨FLT3£©Í»±äµÄ¿ÉÄÜ£¬£¬ £¬£¬£¬¶øº£ÄÚÏÖÔÚ»¹Ã»ÓÐÕë¶ÔFLT3Í»±äÒѱ»»ñÅúÉÏÊеİÐÏòÒ©Îï¡£¡£¡£

 

×÷Ϊ°²Ë¹Ì©À´µÚÒ»¸öѪҺÖ×ÁöµÄÁ¢ÒìÒ©Î£¬ £¬£¬£¬XOSPATA¶ÔFLT3-ITD¼°FLT3-TKD¾ùÓÐÏÔÖøµÄÒÖÖÆ×÷Ó㬣¬ £¬£¬£¬ÊÇÃÀ¹úʳÎïÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨FDA£©Åú×¼µÄÊ׸öÓÃÓÚ¸´·¢»òÄÑÖÎÐÔAMLµÄFLT3ÒÖÖÆ¼Á£¬£¬ £¬£¬£¬ÔÚÃÀ¹ú¡¢ÈÕ±¾¡¢Å·Ã˲¿·Ö¹ú¼Ò¼°ÆäËû¹ú¼ÒºÍµØÇøÊµÏÖÁË»¼Õ߿ɼ°¡£¡£¡£¹ú¼ÊȨÍþҽѧÆÚ¿¯¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·Ôø½ÒÏþ¹ýÆÀ¹ÀXOSPATA IIIÆÚADMIRALÊÔÑéµÄЧ¹û4£¬£¬ £¬£¬£¬Ð§¹ûÏÔʾXOSPATAÖÎÁƵϼÕßµÄ×ÜÉúÑļ°»º½âÂʾùÏÔÖø¸ßÓÚ½ÓÊܱê×¼Õü¾ÈÐÔ»¯ÁƵϼÕß¡£¡£¡£


2020Äê3ÔÂ24ÈÕ£¬£¬ £¬£¬£¬¼ªÈðÌæÄáÔÚÖйúÌá½»ÉÏÊÐÉêÇ룬£¬ £¬£¬£¬7ÔÂ21ÈÕ¼´»ñµÃÓÅÏÈÉóÆÀ×ʸñ£¬£¬ £¬£¬£¬11ÔÂ19ÈÕ±»ÄÉÈëµÚÈýÅúÁÙ´²¼±Ðè¾³ÍâÐÂÒ©Ãûµ¥¡£¡£¡£ÔÚ¹ú¼Ò½ÓÊÜÒ©Æ·¾³ÍâÁÙ´²ÊÔÑéÊý¾Ý¡¢¼ò»¯¾³ÍâÒÑÉÏÊÐÒ©Æ·Èë¿ÚÉóÅúµÄÅä¾°Ï£¬£¬ £¬£¬£¬XOSPATAÓÐÍû¼ÓËÙÔÚÖйúµÄ»ñÅúÉÏÊУ¬£¬ £¬£¬£¬ÔçÈÕΪº£ÄÚFLT3Í»±äµÄAML»¼Õß´øÀ´Í»ÆÆÐÔÖÎÁƼƻ®¡£¡£¡£

 

ÔÙ¶ÈЯÊÖÉÏàÖú£¬£¬ £¬£¬£¬¹²ÍØÐÂÌØÒ©¿É¼°ÐÔ

ÊÜÕïÁƼƻ®¡¢¼²²¡ÈÏ֪ˮһÂÉÒòËØµÄÓ°Ï죬£¬ £¬£¬£¬ÍâÑóÁ¢ÒìÒ©½øÈëÖйúÊг¡£¡£¡£¬£¬ £¬£¬£¬ÔõÑùÔÚרÀûÆÚÄÚ¿ìËÙ½«²úÆ·½á¹¹µ½ÖÕ¶ËÊг¡£¡£¡£¬£¬ £¬£¬£¬ÊµÊ±Îª»¼ÕßÌṩ¼²²¡ÖÎÁƽâ¾ö¼Æ»®£¬£¬ £¬£¬£¬ÊÇÒ©Æ·»ñÅúÉÏÊкóÃæÁÙµÄØ½´ý½â¾öµÄÎÊÌâ¡£¡£¡£


°²Ë¹Ì©À´×÷ΪȫÇòÁìÏȵÄÁ¢ÒìÐÍÖÆÒ©ÆóÒµ£¬£¬ £¬£¬£¬ÖÂÁ¦ÓÚ½«Á¢Òì¿ÆÑ§×ª±äΪҽÁƽâ¾ö¼Æ»®£¬£¬ £¬£¬£¬ÎªÈ«Çò»¼Õß´øÀ´¼ÛÖµºÍÏ£Íû¡£¡£¡£ÖйúÊг¡µÄ¿ªÍؽṹ£¬£¬ £¬£¬£¬Êǰ²Ë¹Ì©À´È«ÇòÕ½ÂÔÖеÄÖ÷Òª×é³É²¿·Ö¡£¡£¡£


×÷ΪÖйúרҵµÄµÚÈý·½Ò½Ò©ÉÌÒµ»¯Æ½Ì¨£¬£¬ £¬£¬£¬bwin±ØÓ®Í¨¹ýÈ«ÇþµÀÁýÕÖ¡¢¶àÆ·ÀàЭͬÒÔ¼°Êý×Ö»¯ÓªÏúµÄ²î±ð»¯ÄÜÁ¦£¬£¬ £¬£¬£¬¾ßÓÐΪÉÏÓι¤ÒµÆóÒµÌṩȫÇþµÀ½â¾ö¼Æ»®µÄʵÁ¦¡£¡£¡£´Ëǰ£¬£¬ £¬£¬£¬°²Ë¹Ì©À´ÒÑÓëbwin±ØÓ®Ç£ÊÖÏàÖú£¬£¬ £¬£¬£¬Æì϶à¸öÔ­ÑÐÒ©¾ù»ñµÃÁ˺£ÄÚÊг¡·Ý¶îµÄÏÔÖøÌáÉý¡£¡£¡£


¾ÝÏàʶ£¬£¬ £¬£¬£¬´Ë´ÎÏàÖúÒâÏòÇ©Êðºó£¬£¬ £¬£¬£¬Ë«·½Ç¨¾ÍXOSPATAµÄÈë¿Ú±£Ë°Í¨¹Ø¡¢²Ö´¢ÎïÁ÷µÈÒ»Ì廯ЧÀÍ£¬£¬ £¬£¬£¬ÒÔ¼°È«ÇþµÀÉÌÒµ»¯Æ½Ì¨½â¾ö¼Æ»®¿ªÕ¹½øÒ»²½µÄ̽ÌÖ£¬£¬ £¬£¬£¬ÌáÉýÖйúAML»¼ÕßµÄÓÃÒ©¿É¼°ÐÔ¡£¡£¡£


×÷Ϊºã¾ÃµÄÏàÖúͬ°é£¬£¬ £¬£¬£¬°²Ë¹Ì©À´¶Ôbwin±ØÓ®ÉÌÒµ»¯Æ½Ì¨µÄ¼ÛÖµºÍÓÅÊÆ³äÂúÐÅÐÄ£¬£¬ £¬£¬£¬´Ë´ÎÓëbwin±ØÓ®ÔÙ¶ÈЯÊÖ£¬£¬ £¬£¬£¬½«¸ÄÉÆÖйúAMLÁìÓòδ±»Öª×ãµÄÖÎÁÆÐèÇ󣬣¬ £¬£¬£¬Îª»¼Õß¼°Æä¼ÒÈË´øÀ´ÐµÄÏ£Íû¡£¡£¡£

 

Çൺ¿Ú°¶Ö±´ï£¬£¬ £¬£¬£¬Íƶ¯¡°Ò»´øÒ»Æð¡±¿µ½¡¾­Ã³ÏàÖú

ÓëÈÕ±¾¸ôº£ÏàÍûµÄÇൺ£¬£¬ £¬£¬£¬¾ßÓÐÉî¶ÈÈÚÈë¡°Ò»´øÒ»Æð¡±µÄÇøÎ»ÓÅÊÆ¡£¡£¡£2019Ä꣬£¬ £¬£¬£¬ÖÐÑëÖÜÈ«ÉˢÐÂίԱ»áµÚ¾Å´Î¾Û»áÉóÒéͨ¹ýÁË¡¶Öйú¡ªÉϺ£ÏàÖú×éÖ¯µØ·½¾­Ã³ÏàÖúÊ÷Ä£Çø½¨Éè×ÜÌ弯»®¡·£¬£¬ £¬£¬£¬ÒªÔÚÉϺÏÊ÷Ä£ÇøÇൺ´òÔì¡°Ò»´øÒ»Æð¡±¹ú¼ÊÏàÖúÐÂÆ½Ì¨£¬£¬ £¬£¬£¬Íƶ¯¹¤¾ßË«Ïò»¥¼Ã¡¢Â½º£ÄÚÍâÁª¶¯µÄ¿ª·ÅÃûÌᣡ£¡£×÷Ϊפ×ãÓÚÇൺ±¾ÍÁµÄÒ½Ò©ÐÐÒµÁúÍ·ÆóÒµ£¬£¬ £¬£¬£¬bwin±ØÓ®ÏȺóÓëÈÕ±¾¶à¼Ò×ÅÃûÒ©Æó½¨ÉèÏàÖú£¬£¬ £¬£¬£¬Æð¾¢ÈÚÈë¡°Ò»´øÒ»Æð¡±¹ú¼ÊÏàÖúÐÂÆ½Ì¨µÄÕ½ÂÔ¡£¡£¡£


ÖµµÃ×¢ÖØµÄÊÇ£¬£¬ £¬£¬£¬ÔÚ´Ë´ÎÓ밲˹̩À´µÄÏàÖúÖУ¬£¬ £¬£¬£¬ÓµÓÐÍêÉÆµÄÒ©Æ·Èë¿Ú×ÊÖʼ°º£¹ØAEOÈÏÖ¤×ÊÖʵÄbwin±ØÓ®£¬£¬ £¬£¬£¬ÏÔʾ³öÆäǿʢµÄÍâÑóÒ©Æ·Èë¿ÚӪҵʵÁ¦¡£¡£¡£ÎÞÂÛÊÇÈë¿Ú±£Ë°Í¨¹Ø¡¢ÀäÁ´¿â·¿ÕվɸßЧÎïÁ÷ÅäËÍ£¬£¬ £¬£¬£¬¶¼ÓÐרҵµÄÈë¿Ú²Ù×÷ÍŶӾÙÐÐÈ«Á÷³ÌЧÀÍ£¬£¬ £¬£¬£¬ÎªÍâÑóÒ©Æ·Êèͨ¹ú¼ÊÎïÁ÷ͨµÀ¡£¡£¡£ÔÚ¾­ÓÉÊ×´ÎÈë¿ÚÁ÷³Ìºó£¬£¬ £¬£¬£¬XOSPATA±ã¿Éͨ¹ý¿ÕÔË·½·¨£¬£¬ £¬£¬£¬Ö±½Ó´ÓÈÕ±¾ÓÉÇൺ¿Ú°¶½øÈëÖйú£¬£¬ £¬£¬£¬ÌáÉýЧÂÊ£¬£¬ £¬£¬£¬½µµÍ±¾Ç®¡£¡£¡£


˳Ӧ¿µ½¡¹¤ÒµÉú³¤Ç÷ÊÆ£¬£¬ £¬£¬£¬bwin±ØÓ®×÷Ϊ¹¤ÒµÁ´ÏÂÓÎרҵµÄµÚÈý·½ÉÌÒµ»¯Æ½Ì¨£¬£¬ £¬£¬£¬ÖúÁ¦ÐÐÒµÓÅ»¯×ÊÔ´£¬£¬ £¬£¬£¬ÌáÉýЧÂÊ¡£¡£¡£½üÄêÀ´£¬£¬ £¬£¬£¬bwin±ØÓ®ÉÌÒµ»¯Æ½Ì¨ÎüÒýÁËÖÚ¶àÏàÖúͬ°é£¬£¬ £¬£¬£¬ÂõÀ¶¡¢Î÷°²ÑîÉ­¡¢ÎäÌï¡¢½ÜÌØ±´ÁÖ¡¢ÑÅÅàµÈº£ÄÚÍâÖ÷Á÷Ò©Æó¶¼Óëbwin±ØÓ®¸æ¿¢ÁËÎȹÌÏàÖú¹ØÏµ¡£¡£¡£³Ð¼ÌΪȫÉç»áÌṩ¸üºÃµÄÒ½ÁÆ¿µ½¡²úÆ·ºÍЧÀ͵ÄʹÃü£¬£¬ £¬£¬£¬bwin±ØÓ®½«Ò»Á¬Ê©Õ¹ÉÌÒµ»¯Æ½Ì¨µÄרҵÄÜÁ¦£¬£¬ £¬£¬£¬´î½¨¸ü¶àÍâÑóÒ©ÆóÓ뺣ÄÚÊг¡ÅþÁ¬µÄ¡°ÇÅÁº¡±£¬£¬ £¬£¬£¬ÈÃÖйúµÄÀÏÀèÃñÄÜÓÃÉϹú¼ÊÆ·ÖʵĺÃÒ©¡£¡£¡£


²Î¿¼ÎÄÏ×£º

1 GLOBOCAN Cancer Today Database, International Agency for Research on Cancer, World Health Organisation. Population Fact Sheets in 2018.

2 GLOBOCAN Cancer Today Database, International Agency for Research on Cancer, World Health Organisation. Population Fact Sheets in 2018.

3 American Cancer Society. Risk Factors for Acute Myeloid Leukemia (AML).

4 Perl A, Martinelli G, Cortes J, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019; 381:1728-40.


·µ»Ø¶¥²¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿